ursodeoxycholic acid has been researched along with Adenocarcinoma of Lung in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujioka, M; Genda, T; Hara, M; Iwakami, N; Iwakami, SI; Kurokawa, K; Miyashita, Y; Sasaki, S; Takahashi, K | 1 |
| Brackett, LM; Reddy, CA; Schneider, BJ; Tai, AW | 1 |
| Descourt, R; Fouchard, M; Jantzem, H; Poureau, PG; Quere, G; Robinet, G | 1 |
3 other study(ies) available for ursodeoxycholic acid and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Cholestasis; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bile Duct Diseases; Cholagogues and Choleretics; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunotherapy; Lung Neoplasms; Middle Aged; Nivolumab; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholagogues and Choleretics; Cholangitis; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Treatment Outcome; Ursodeoxycholic Acid | 2019 |